MX2022000250A - Streptomyces clavuligerus. - Google Patents

Streptomyces clavuligerus.

Info

Publication number
MX2022000250A
MX2022000250A MX2022000250A MX2022000250A MX2022000250A MX 2022000250 A MX2022000250 A MX 2022000250A MX 2022000250 A MX2022000250 A MX 2022000250A MX 2022000250 A MX2022000250 A MX 2022000250A MX 2022000250 A MX2022000250 A MX 2022000250A
Authority
MX
Mexico
Prior art keywords
ccar
streptomyces clavuligerus
mutation
seq
site corresponding
Prior art date
Application number
MX2022000250A
Other languages
English (en)
Inventor
Andrew John Collis
Nicola Crowhurst
Katherine Joyce Honicker
Steven Gary Kendrew
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1909698.1A external-priority patent/GB2585246B/en
Priority claimed from GBGB2005327.8A external-priority patent/GB202005327D0/en
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2022000250A publication Critical patent/MX2022000250A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a una cepa de Streptomyces clavuligerus que comprende dos mutaciones puntuales en una región promotora de ccaR y una mutación de sustitución en el gen ccaR, en donde las mutaciones en la región promotora de ccaR son una mutación puntual de C a T en un sitio que corresponde a la posición 48 de SEQ ID NO: 1 y una mutación puntual de G a A en un sitio que corresponde a la posición 143 de SEQ ID NO: 1; y en donde la mutación en el gen ccaR es una sustitución de arginina a triptófano en un sitio que corresponde a la posición 32 de SEQ ID NO: 2. La invención también se refiere a un método para usar esta cepa de Streptomyces clavuligerus para producir ácido clavulánico.
MX2022000250A 2019-07-05 2020-07-03 Streptomyces clavuligerus. MX2022000250A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909698.1A GB2585246B (en) 2019-07-05 2019-07-05 Streptomyces clavuligerus
GBGB2005327.8A GB202005327D0 (en) 2020-04-09 2020-04-09 Streptomyces clavuligerus
PCT/EP2020/068761 WO2021004912A1 (en) 2019-07-05 2020-07-03 Streptomyces clavuligerus

Publications (1)

Publication Number Publication Date
MX2022000250A true MX2022000250A (es) 2022-02-03

Family

ID=71523132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000250A MX2022000250A (es) 2019-07-05 2020-07-03 Streptomyces clavuligerus.

Country Status (5)

Country Link
EP (1) EP3994154A1 (es)
KR (1) KR20220031043A (es)
CN (1) CN114072493A (es)
MX (1) MX2022000250A (es)
WO (1) WO2021004912A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113755517B (zh) * 2021-10-18 2023-04-07 安徽大学 一种slcg_5407基因改造型林可链霉菌的构建方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9702218D0 (en) 1997-02-04 1997-03-26 Smithkline Beecham Plc Novel product
KR100499812B1 (ko) 1997-02-14 2005-07-08 스미스클라인 비참 코포레이션 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형
PL206316B1 (pl) 2000-05-13 2010-07-30 Smithkline Beecham Plcsmithkline Beecham Plc Sposób wytwarzania klawulanianu potasu
US7517680B2 (en) * 2005-09-09 2009-04-14 Johns Hopkins University Production of clavulanic acid by genetic engineering of Streptomyces clavuligerus
CN103013865A (zh) * 2012-12-04 2013-04-03 天津师范大学 一种棒状链霉菌的工程菌株及其制备方法与应用
CN108938746A (zh) * 2018-10-10 2018-12-07 新昌县九信药业有限公司 一种复方阿莫西林粉及其制备方法

Also Published As

Publication number Publication date
KR20220031043A (ko) 2022-03-11
CN114072493A (zh) 2022-02-18
WO2021004912A1 (en) 2021-01-14
EP3994154A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
EP4286407A3 (en) Anti-mutated kras t cell receptors
WO2016122146A1 (en) Novel promoter and uses thereof
JP2018522565A5 (es)
WO2021097452A3 (en) Biosynthetic production of psilocybin and related intermediates in recombinant organisms
CN101633901B (zh) 一种用于重组工程的大肠杆菌菌株
NZ600189A (en) Novel 7beta-hydroxysteroid dehydrogenases and their use
MX2022000250A (es) Streptomyces clavuligerus.
CA2900580C (en) Method for producing l-lysine by modifying aconitase gene and/or regulatory elements thereof
WO2018144551A3 (en) D-methadone and its derivatives for use in the treatment of disorders of the nervous system
AR033857A1 (es) Cepas de levaduras que producen esteroides de forma autonoma.
IL187341A0 (en) Scalable fermentation process
MA33921B1 (fr) Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia
MX2019007406A (es) Especie de metschnikowia productora de xilitol.
Qin et al. Improvement of clavulanic acid production in Streptomyces clavuligerus F613-1 by using a claR-neo reporter strategy
BR112021017340A2 (pt) Cepas de paenibacillus e métodos para uso das mesmas
MY183660A (en) Novel mutant microorganism producing succinic acid simultaneously using sucrose and glycerol, and method for preparing succinic acid using same
MX2021008017A (es) Formulaciones de colagenasa y metodos de produccion de las mismas.
MY170467A (en) High molecular weight pha-producing microbe and method of producing high molecular weight pha using same
JP2019047790A (ja) Ｌ−アミノ酸を生産する微生物、及びそれを利用してｌ−アミノ酸を生産する方法
AU2018274028A1 (en) A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
JP5042186B2 (ja) 多量のクラブラン酸を産生する微生物
EP1948679A4 (en) METHOD FOR PREPARING A RECOMBINANT PEPTIDE FROM SPIDER VENOM AND ANALGESIC COMPOSITION CONTAINING THE PEPTIDE
JP6599583B1 (ja) 多重遺伝子破壊アスペルギルス属微生物及びその製造方法
MX2020010422A (es) Alfa-amilasa maltogenica variante.
PH12021550424A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants